CTOs on the Move

Helping Hands Family

www.hhfamily.com

 
Helping Hands Family is a group of ABA therapy clinics in PA, NJ, NY, MD, & CT that provides personalized Applied Behavior Analysis (ABA) therapy to help children with autism socialize, learn, and grow.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.hhfamily.com
  • 640, Freedom Business Center Drive
    King of Prussia, PA USA 19406
  • Phone: 484.965.9966

Executives

Name Title Contact Details

Similar Companies

Amalgamated Life and Health

Amalgamated Life and Health is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Allergy and Asthma Care

Allergy and Asthma Care is a Germantown, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

H2h Solutions

Established in July 2000, H2H Solutions is a spin-off of Youngsoft Inc., a leading software development and consulting services company with corporate offices in Wixom, Michigan and Parsippany, New Jersey, USA. Youngsoft is also a Certified Minority

American Viatical Svc

American Viatical Svc is a Woodstock, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ContraVir Pharmaceuticals, Inc

ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.